Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1997 3
1998 1
2000 2
2001 1
2011 1
2013 1
2016 3
2017 1
2018 2
2019 3
2020 2
2021 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
Cortese M, Munger KL, Martínez-Lapiscina EH, Barro C, Edan G, Freedman MS, Hartung HP, Montalbán X, Foley FW, Penner IK, Hemmer B, Fox EJ, Schippling S, Wicklein EM, Kappos L, Kuhle J, Ascherio A; BENEFIT Study Group. Cortese M, et al. Among authors: wicklein em. Neurology. 2020 May 5;94(18):e1950-e1960. doi: 10.1212/WNL.0000000000009371. Epub 2020 Apr 16. Neurology. 2020. PMID: 32300060 Free PMC article. Clinical Trial.
CFD for wastewater treatment: an overview.
Samstag RW, Ducoste JJ, Griborio A, Nopens I, Batstone DJ, Wicks JD, Saunders S, Wicklein EA, Kenny G, Laurent J. Samstag RW, et al. Among authors: wicklein ea. Water Sci Technol. 2016;74(3):549-63. doi: 10.2166/wst.2016.249. Water Sci Technol. 2016. PMID: 27508360 Review.
Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
Manuel Escobar J, Cortese M, Edan G, Freedman MS, Hartung HP, Montalbán X, Sandbrink R, Radü EW, Barkhof F, Wicklein EM, Kappos L, Ascherio A, Munger KL. Manuel Escobar J, et al. Among authors: wicklein em. Mult Scler. 2022 Jul;28(8):1277-1285. doi: 10.1177/13524585211061861. Epub 2022 Jan 7. Mult Scler. 2022. PMID: 34994579 Free PMC article.
Sodium intake and multiple sclerosis activity and progression in BENEFIT.
Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group. Fitzgerald KC, et al. Among authors: wicklein em. Ann Neurol. 2017 Jul;82(1):20-29. doi: 10.1002/ana.24965. Ann Neurol. 2017. PMID: 28556498 Free PMC article. Clinical Trial.
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM; IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators. Goodin DS, et al. Among authors: wicklein em. Mult Scler. 2019 May;25(6):837-847. doi: 10.1177/1352458518773511. Epub 2018 May 15. Mult Scler. 2019. PMID: 29761737
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B; BEYOND and BENEFIT Study Groups. Buck D, et al. Among authors: wicklein em. Mult Scler. 2019 Apr;25(4):565-573. doi: 10.1177/1352458518763089. Epub 2018 Mar 9. Mult Scler. 2019. PMID: 29521573 Clinical Trial.
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group. Kappos L, et al. Among authors: wicklein em. Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10. Neurology. 2016. PMID: 27511182 Free PMC article. Clinical Trial.
22 results